NSABP Members' Area
  Password Protected - Access
  Limited to NSABP Participating
  Institutions Only

NSABP Foundation, Inc.

General NSABP Information
  Financial Conflicts of
     Interest Policy
  Coalition Comment:
  IOM Report Group Comment
  Contact the NSABP
  Pathology Section
  Future Meetings
  NSABP Newsletters
  Media Info on STAR

Clinical Trials Information
  Clinical Trials Overview
  Protocol Chart
  Never Say Lost

Treatment Trials Information
  Protocol B-51
  Protocol B-52
  Protocol B-53/S1207
  Protocol B-55/BIG 6-13

Prevention Trials Information
  Protocol P-1 - BCPT
  Protocol P-2 - STAR
  Protocol P-5

Scientific Publications

Related Web Sites

Medical Search Engines

To report problems, ask
questions or make comments,
please send e-mail to:

NSABP Clinical Trials Overview

Protocol R-02
A Protocol to Compare Adjuvant MeCCNU, Vincristine and 5-Fluorouracil (MOF), With and Without Radiation, to Adjuvant Leucovorin and 5-Fluorouracil (LV+5FU), With and Without Radiation, in Patients with Dukes' B and C Carcinoma of the Rectum

Specific Aims
Protocol R-02 has been designed to determine if the addition of radiation therapy to chemotherapy improves disease-free survival and survival in patients with Dukes' B and C carcinoma of the rectum. Based on findings in Protocol R-01, males are randomized to one of four treatment regimens: MOF, MOF+RT, LV+5FU, or LV+5FU+RT; females are randomized to one of two treatment regimens: LV+5FU or LV+5FU+RT. Specific aims are: (1) to determine whether radiation, when added to a chemotherapeutic regimen, prolongs disease-free survival and survival; (2) for males only, to compare MOF, with and without radiation, to LV+5FU, with and without radiation; and (3) for males and females, to compare LV+5FU without radiation to LV+5FU with radiation.